Search - tctmd.com

Displaying 81 - 100 of 239

Sort: Relevancy | Date

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31997-X/fulltext

News Conference News ESC 2019

Ten-Year SYNTAXES Results Fix Roles for CABG, PCI in Complex CAD

Shelley Wood

September 05, 2019

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Shelley Wood

September 04, 2019

News Conference News ESC 2019

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Yael L. Maxwell

September 04, 2019

News Conference News ESC 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

Todd Neale

September 04, 2019

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Ruling Out MI Safe With 0/1-Hour High-Sensitivity Troponin: RAPID-TNT

Michael O'Riordan

September 03, 2019

Presentation ESC 2019

Temporal Trends in Incidence and Outcome of Acute Coronary Syndrome

Presenter: Johannes Neumann

September 01, 2019

News Conference News ESC 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

Shelley Wood

September 01, 2019

News Conference News ESC 2019

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

Yael L. Maxwell

September 01, 2019

News Conference News ESC 2019

Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

HiSTORIC Trial Supports Single-Test Rule-Out of MI Using High-Sensitivity Troponin

Todd Neale

September 01, 2019

Presentation ESC 2019

A Cluster Randomized Trial of Objective Risk Assessment Versus Standard Care for Acute Coronary Syndromes

Presenter: David B. Brieger

September 01, 2019

News Conference News ESC 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Yael L. Maxwell

September 01, 2019

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

L.A. McKeown

August 30, 2019

News Daily News

Decline in US Deaths From CVD and Diabetes Is Leveling Off

Todd Neale

August 27, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

Advertisement

Ten-Year SYNTAXES Results Fix Roles for CABG, PCI in Complex CAD

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Long-term Secondary Prevention Post-CABG Important Yet Lacking: SWEDEHEART

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Ruling Out MI Safe With 0/1-Hour High-Sensitivity Troponin: RAPID-TNT

Temporal Trends in Incidence and Outcome of Acute Coronary Syndrome

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS

HiSTORIC Trial Supports Single-Test Rule-Out of MI Using High-Sensitivity Troponin

A Cluster Randomized Trial of Objective Risk Assessment Versus Standard Care for Acute Coronary Syndromes

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Young Survivors of Childhood Cancer Have Higher, Earlier Risk of CVD Events

Decline in US Deaths From CVD and Diabetes Is Leveling Off

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content